INOVIO Pharmaceuticals
NEWS ALERT

FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Press Releases

INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

Posted on October 23, 2025

INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

Posted on October 23, 2025

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

Posted on October 21, 2025

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

Posted on October 21, 2025

INOVIO to Present at Upcoming Scientific Conference

Posted on October 9, 2025

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

Posted on October 9, 2025

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Posted on October 9, 2025

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Posted on October 9, 2025

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Posted on October 9, 2025

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

Posted on October 9, 2025

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

© Copyright 2026 INOVIO Pharmaceuticals. All rights reserved.